Trial Profile
Expanded Access for CC-4047
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Sponsors Celgene Corporation
- 18 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2018 New trial record